Corrigendum: Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma

Corrigendum: Development and validation of a m⁶A -regulated prognostic signature in lung adenocarcinoma

Front Oncol. 2023 Nov 7:13:1309950. doi: 10.3389/fonc.2023.1309950. eCollection 2023.

Yaxin Chen¹, Lei Xia², Yuxuan Peng¹, Gang Wang³, Liyun Bi³, Xue Xiao¹, Cui Li¹, Weimin Li^{1

3

4

5}

¹ Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
² Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, China.
³ Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China.
⁴ Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
⁵ The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, China.

[This corrects the article DOI: 10.3389/fonc.2022.947808.].

Keywords: epitranscriptomic; lung adenocarcinoma; m6A; prognosis; signature.